Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Capital Leases (2022 - 2025)

aTYR PHARMA's Capital Leases history spans 4 years, with the latest figure at $259000.0 for Q4 2025.

  • For Q4 2025, Capital Leases fell 70.8% year-over-year to $259000.0; the TTM value through Dec 2025 reached $259000.0, down 70.8%, while the annual FY2025 figure was $259000.0, 70.8% down from the prior year.
  • Capital Leases reached $259000.0 in Q4 2025 per ATYR's latest filing, down from $398000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $1.6 million in Q1 2023 to a low of $259000.0 in Q4 2025.
  • Average Capital Leases over 4 years is $951000.0, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Capital Leases: surged 411.74% in 2023, then crashed 70.8% in 2025.
  • A 4-year view of Capital Leases shows it stood at $1.0 million in 2022, then soared by 41.81% to $1.4 million in 2023, then tumbled by 37.89% to $887000.0 in 2024, then plummeted by 70.8% to $259000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Capital Leases are $259000.0 (Q4 2025), $398000.0 (Q3 2025), and $602000.0 (Q2 2025).